<DOC>
	<DOCNO>NCT00596271</DOCNO>
	<brief_summary>The objective investigate immunogenicity Japanese Encephalitis vaccine IC51 ( JE-PIV ) single concomitant HAVRIX® 1440</brief_summary>
	<brief_title>Concomitant Vaccination With Japanese Encephalitis Vaccine IC51 HARVIX® 1440</brief_title>
	<detailed_description>This randomize , control , multi-center , single-blind phase 3 study . The study population consist male female healthy subject , age least 18 year . 192 subject enrol 2 site Europe .</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Encephalitis , Japanese</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>At least 18 year age In female subject either childbearing potential terminate surgery one year postmenopausal , negative serum pregnancy test screen willingness become pregnant study period 30 day last vaccination practice reliable method contraception Written inform consent obtain prior study entry History clinical manifestation flavivirus infection History vaccination Japanese encephalitis ( JE ) , Yellow fever Dengue fever ( antiJEV neutralize antibody titer &gt; = 1:10 baseline acceptable inclusion , subject part safety population , analyze immunogenicity perprotocol analysis ) History previous Hepatitis A vaccination infection Use investigational nonregistered drug vaccine addition study vaccine study period within 30 day precede first dose study vaccine Planned administration another vaccine study period Immunodeficiency include postorgantransplantation immunosuppressive therapy A family history congenital hereditary immunodeficiency History autoimmune disease Administration chronic ( defined 14 day ) immunosuppressant immunemodifying drug within six month vaccination . Any acute infection within 4 week prior enrollment Infection human immunodeficiency virus ( HIV ) , Hepatitis B ( HBsAg ) Hepatitis C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>